Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

440
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
440
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

485
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
485
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
174
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microinjection of kynurenic acid and lidocaine into the dorsal motor nucleus of vagus evokes airway smooth muscle relaxation in ferrets.

Respiratory physiology & neurobiology·2026
Same author

Application of optical coherence tomography in multiple sclerosis: consensus recommendations of the Austrian network (AN-OCT-MS).

Journal of neurology·2025
Same author

Prognostic factors associated with progression of open-angle glaucoma in adults.

The Cochrane database of systematic reviews·2025
Same author

Effectiveness of intraocular lenses designed to correct presbyopia after cataract surgery: an overview of systematic reviews.

The British journal of ophthalmology·2025
Same author

Serum Neurofilament Light Chain in Patients with Dominant Optic Atrophy - A Case-Control Study.

Neuro-ophthalmology (Aeolus Press)·2025
Same author

Changes of individual retinal layer thickness post-uneventful cataract surgery determined by spectral-domain optical coherence tomography over a 3-months period.

Heliyon·2024

Related Experiment Video

Updated: Jun 29, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.1K

Metformin in Glaucoma Treatment.

Qëndresë Daka1,2, Burim Neziri1, Ewald Lindner3

  • 1Department of Pathophysiology, Medical Faculty, University of Prishtina, Prishtinë, Kosovo.

Journal of Glaucoma
|March 27, 2024
PubMed
Summary
This summary is machine-generated.

Metformin shows potential for glaucoma treatment by modulating neuroprotective pathways, but rigorous clinical trials are needed to confirm its safety and efficacy. Further research is essential to explore its therapeutic benefits.

More Related Videos

Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.2K
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.3K

Related Experiment Videos

Last Updated: Jun 29, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.1K
Ultrasound Cyclo Plasty in Eyes with Glaucoma
05:05

Ultrasound Cyclo Plasty in Eyes with Glaucoma

Published on: January 26, 2018

12.2K
Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis
13:47

Laser Capture Microdissection of Highly Pure Trabecular Meshwork from Mouse Eyes for Gene Expression Analysis

Published on: June 3, 2018

9.3K

Area of Science:

  • Ophthalmology
  • Pharmacology
  • Neuroscience

Background:

  • Glaucoma is a leading cause of irreversible blindness.
  • Current treatments aim to lower intraocular pressure but do not fully prevent vision loss.
  • Metformin, a diabetes drug, has shown potential neuroprotective properties.

Purpose of the Study:

  • To evaluate the potential benefits of metformin in glaucoma.
  • To investigate the mechanisms underlying metformin's effects on glaucoma risk factors.
  • To contribute to developing novel glaucoma treatment strategies.

Main Methods:

  • Systematic search of electronic databases (PubMed, EMBASE, ClinicalTrials.gov).
  • Inclusion of studies assessing metformin's effects on glaucoma risk factors and mechanisms.
  • Analysis of experimental data for neuroprotective pathways.

Main Results:

  • No clinical trials specifically investigating metformin for glaucoma were identified.
  • Experimental studies indicate metformin can modulate pathways relevant to neuroprotection in glaucoma.
  • Metformin's ability to affect pathways like AMPK and reduce oxidative stress was noted.

Conclusions:

  • Metformin exhibits potential therapeutic properties for glaucoma based on experimental data.
  • Rigorous clinical trials are essential to establish metformin's safety and efficacy in glaucoma patients.
  • Further research is required to fully harness metformin's therapeutic potential in comprehensive glaucoma treatment strategies.